---
layout: post
title: "Discussion Paper: Artificial Intelligence in Drug Manufacturing, Notice; Request for Information and Comments"
date: 2026-02-05 18:35:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-04206
original_published: 2023-03-01 00:00:00 +0000
significance: 8.00
---

# Discussion Paper: Artificial Intelligence in Drug Manufacturing, Notice; Request for Information and Comments

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 01, 2023 00:00 UTC
**Document Number:** 2023-04206

## Summary

The Food and Drug Administration (FDA or Agency) is announcing publication of a discussion paper providing information for stakeholders and soliciting public comments on a specific area of emerging and advanced manufacturing technologies. The discussion paper presents areas for consideration and policy development identified by the Center for Drug Evaluation and Research (CDER) scientific and policy experts associated with application of artificial intelligence (AI) to pharmaceutical manufacturing. The discussion paper includes a series of questions to stimulate feedback from the public, including CDER and the Center for Biologics Evaluation and Research (CBER) stakeholders.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/01/2023-04206/discussion-paper-artificial-intelligence-in-drug-manufacturing-notice-request-for-information-and)
- API: https://www.federalregister.gov/api/v1/documents/2023-04206

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
